Enveric Biosciences Inc vs Alphabet Inc Class A — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Alphabet Inc Class A trades at $353.62 (market cap $4.52T). The key difference: Alphabet Inc Class A is far larger — about 849624.1× Enveric Biosciences Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | GOOGL | |
|---|---|---|
Market Cap | $5.32M | $4.52T |
Sector | Health | Media |
52-Week High | $17.40 | $402.62 |
52-Week Low | $1.28 | $182.97 |
Enterprise Value | $408.82K | $4.49T |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Alphabet (GOOGL) trades at $356.14, down 0.94% on the day, with strong technical support at $355 and resistance at $375. The stock shows bullish momentum in moving averages while oscillators remain neutral. Recent earnings consistently beat expectations, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 forecast. Revenue growth accelerated to $402.84 billion in 2025, with net income margins expanding to 32.8%.
Alphabet presents a compelling investment case with 85% analyst buy ratings and a $431.78 consensus price target representing 21% upside. Strong AI integration, YouTube price increases, and cloud partnerships drive growth, though regulatory scrutiny and tech sector volatility remain key risks. The company's robust cash flow generation and strategic investments position it well for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →